Jin Won Kim

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 986 citations

Placebo Monotherapy, Health Sciences, Gastrointestinal Oncology +15

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

Jin Won Kim, Kyung Han Nam, Sang-Hoon Ahn et al. · Gastric Cancer · 2014 · 248 citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +11

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

Nick Pavlakis, Katrin Marie Sjoquist, Andrew Martin et al. · Journal of Clinical Oncology · 2016 · 238 citations · Full text

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Clinical Oncology · 2022 · 230 citations

Immunology, Pathology, Immunotherapeutics +18